The prophylactic and therapeutic efficacies of the immunomodulating agent RU 41 .740 (a glycoprotein extract from Klebsiella pneumoniae) were studied in a murine model of intra-abdominal abscess formation with Bacteroides fragilis, Escherichia coli, and bran as an abscess-potentiating agent. Parenteral injection of RU 41 .740, either before or after injection of an abscess-inducing mixture (AIM), was associated with significantly diminished incidence and size of abscesses. Abscess incidence and size were significantly decreased by oral administration of RU 41 .740 after, but not before, AIM injection. Abscess formation and resolution are the results of complex interactions of host defence mechanisms with bacteria and potentiating agent, and RU 41 .740 has been shown previously to activate both macrophage and neutrophil function. These results indicate that activation of non-specific defences may protect against abscess development in chronic sepsis.
Introduction
Biological response modifiers (BRMs) are a group of heterogeneous substances that augment or diminish specific immune responses. Of particular interest has been their capability to augment host immune responses to malignant cells1. and infectious agents3 BRMs may also diminish immune responses in transplant rejection and autoimmune disease (e.g., cyclosporin A).' Some BRMs are extracts or products of micro-organisms, and have modulating activities that augment non-specific host defences.
RU 41.740 comprises a mixture of molecules, predominantly glycoproteins from the cell wall of Klehsiellu pnmrnoniae, and is an example of a BRM that augments responses of 1ymphocytes,'v6 macrophages,' lo and neutrophils."-l4 When used prophylactically. either parenterally or orally, it significantly protects animals against lethal parenteral challenges with Streptococcus pneurnoniae, Listeria rnonticy*toqenes. Staphjdococcus aureus, K . pneumoniae, and several viruses,'" as well as Candida sp. 16 Its efficacy has not been tested in models of chronic bacterial infection.
We have examined the ability of RU 41.740 to inhi bit intra-abdominal abscess development in an experimental model in mice," in which lesions and viable bacteria persist for months,17 and bacteria are sequestered within abscess neutrophils.1s-2"
Materials and methods

Abscess induct ion
Intra-abdominal abscesses were induced in 6-1 2week-old male BALB/c mice as described previo~s1y.l~ Briefly, mice (usually in groups of 10) were given, by intraperitoneal (i.p.) injection, 0.05 ml of an abscessinducing mixture (AIM) comprising 1 mg of bran as potentiating agent, (0-5-2.0) x lo6 cfu of Escherichia coli and (0.2-4.0) x lo9 cfu of Bacteroides fragilis. The bacteria were taken from stocks frozen at -80°C. The AIM was prepared and loaded into syringes in an anaerobic chamber. Samples were taken for quantification of bacteria at the time of injection. Mice were killed by cervical dislocation 6 or 7 days after being given the AIM and examined for the presence of intra-abdominal abscesses. The location, number and weight of abscesses were determined, and representative abscesses were assayed for bacterial content as described previous1y.l' Immunopo ten tiating agent RU 41.740 (BiostimB; Roussel UCLAF, Paris) is an extract of K. pneumoniae strain K201 obtained by lysis, organic extraction, centrifugation and ultra-fi1trati0n.l~ The mixture of molecules comprises c. 50% of " P l " glycoprotein (95.5 kDa), c. 20% of "F1" glycoprotein (350 kDa), and c. 10% of "F2" glycoprotein (65-100 kDa), with the remaining 20% containing lipids, nucleic acids, water and mineral salts. The batch number of the compound used was R 83-A-683 1. A stock solution of RU 41.740 dissolved in mouse-osmolality phosphate-buffered saline (MPBS),21 was stored at 4°C until use. Doses of 0.01-0.30 mg were used, usually in volumes of 0.4 ml given by i.p. injection or 0.2 ml given subcutaneously (s.c.), or doses of 0.25-4-0mg in 0.1 ml were given orally. Control mice were given a similar volume of MPBS only.
Quantijication of bacteria
Timing of injection
When RU 41.740 was used prophylactically, the indicated doses were given 5, 3 and 1 days before the AIM. When RU 41.740 was used therapeutically, it was given on days 2,4 and 6 after the AIM.
Statistical analysis
For the comparison of mortality or abscess incidence in groups of mice, Fisher's exact test was used. 22 For the comparison of abscess sizes or bacterial contents between groups, the non-parametric Mann-Whitney U-test was employed.22
Results
RU 41.740 given i.p. before injection of AIM at the same site
The results of three experiments in which RU 41.740 was administered by i.p. injection in three doses before injection of AIM are shown in table I. In the first experiment, three doses of 0.1 mg/mouse protected the recipients against challenge with an AIM. In the second experiment, the bacterial challenge in AIM was doubled and 0.2 mg, but not 0.1 mg, of RU 41.740/mouse/dose was protective. In the third experiment, the bacterial inoculum was increased further and there was significant mortality within 24 h of AIM injection in control mice. In mice given three doses of 0-3 mg of RU 41.740, there was significant protection against both the early mortality and subsequent abscess incidence. In a fourth experiment (data not shown), a single 0-2-mg dose of RU 41.740 given by i.p. injection 1 day before challenge with AIM gave significant protection against intra-abdominal abscess formation. RU 71.740 given i.p. after i.p. injection of an AIM Treatment with RU 41.740 in doses of 0.2 mg/ mouse, i.p., after injection of AIM, did not diminish abscess incidence (100 YO in both groups). However, the median abscess burden in the treated group (33 mg; range 2-267 mg) was significantly less than that in the control group (163 mg; range 55-519 mg; p < 0.05 in the Mann-Whitney test).
RU 41.740 given S.C. before i.p. injection of an AIM
The results of two experiments in which three doses of RU 41.740 were given by S.C. injection before i.p. injection of an AIM are given in table 11. A dose of 
RU41.740 given orally
The experiments described above indicated that parenteral injection of RU 41.740, either at the site of sepsis (i.p.) or at a site distant from it (s.c.), before or after initiation of infection, significantly diminished abscess incidence or size or both. However, clinical use of the agent would be facilitated by oral administration. Other experimental studies indicated that oral RU 41 .740 could protect against lethal parenteral challenge with various microbial ~ath0gens.l~. l6 Therefore, oral administration at doses effective in these models, before and after i.p. injection of an AIM, was examined. An oral dose of 1 mg/mouse on each of days 2,4 and 6 after i.p. injection of the AIM inhibited abscess development ; a similar dose given on days -5, -3 and -1 did not; increased doses of RU 41 .740 given before AIM challenge were also ineffective (table  IV) .
Bacterial content of abscesses
Representative abscesses from control and treated groups were examined by quantitative culture in most experiments. The bacterial content (cfu/mg) of abscesses that developed in RU 41.740-treated mice was not significantly different from that of abscesses of similar size in control mice.
Discussion
In these experiments, injection of an immunopotentiating agent, RU 41 .740, diminished abscess incidence or size when given parenterally either at the site of challenge (i.p.), or remote from it (s.c.), before or after AIM challenge. When used prophylactically, RU 41 .740 inhibited abscess development.
As RU 41.740 is extracted from K. pneumoniae, it might be argued that contaminating lipopolysaccharide could produce some of the effects seen. However, analysis of its constituents has shown that glycoproteins are the major components.15 Further-more, one of the effects of RU 41 .740, stimulation of B lymphocytes, has been reproduced in a strain of mice that is unresponsive to polyclonal B-cell activation by lipopol ysaccharide.
When parenteral RU 41.470 was used therapeutically (i.e., after injection of AIM), inhibition of abscess development was less marked than with prophylactic administration. Abscess size and bacterial contents were significantly diminished. It is possible that the diminished abscess size may have resulted from the " diversion " of neutrophils from the encapsulated lesion (the abscess) to the site of RU 41 .740 injection. However, abscesses in treated mice contained viable bacteria at concentrations similar to those in abscesses of equivalent size in control mice indicating that the host was not compromised. This is an important aspect of the effect of RU 41 .470, as the size and bacterial content of abscesses is likely to correlate with the extent of clinical problems posed by abscesses.
When given by S.C. injection, RU 41.740 produced some dermonecrosis. It has been suggested that the oral route is effective for RU 41 .740, and has a much higher LD50 than the parenteral With this, and the clinical usefulness of oral administration in mind, a series of experiments with oral RU 4 1 .740 was done. RU 41 .740 given by mouth after AIM challenge provided some significant protection against abscess development. Although this modest effect was in contrast to its efficacy when given parenterally, and its reported efficacy with septicaemic infection,15 it may stem from the complexity of the pathogenesis of chronic infection in the abscess model, such as persistence of abscesses in untreated animals for months.17 Bacterial persistence within abscesses is associated with diminished bactericidal activity of neutrophils from abscesses towards those bacteria engulfed in v ivo . T lymphocyte^,^^ and the abscesspotentiating agent essential in this and other both contribute to abscess development in nonimmune hosts. However, it has been demonstrated that RU 41.740 affects both macrophages and neutrophil~,'-~* comprising the likely mechanisms underlying its inhibitory effects on abscess development.
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lnevitably with the proceedings of meetings, the individual contributions vary considerably in content and quality and some have become outdated in the 2 years since they were written. Nevertheless this volume contains useful infor-mation which should be of interest to those involved in the manufacture or quality control of biologicals.
In section 1, the need for a flexible approach in the regulation of biologicals is stressed by Petricciani who points to undue concern over residual contaminating DNA whereas viral contamination poses a real risk. However, even this has to be assessed on a case by case basis as contamination by avian retroviruses of substrates used to prepare influenza and yellow fever vaccines has led to no identified adverse effects. Other contributions emphasise the safe track record of continuous cell lines compared to primary cell cultures and summarise EEC legislation on biologicals,
In section 2, the historical problems encountered in the inactivation of polio and foot and mouth disease viruses for vaccine preparation are discussed, together with proposed procedures for the inactivation of viruses in blood products.
Sections 3 and 4, on BSE and related diseases, contain some of the more interesting contributions to this volume, although inevitably in this topical field some statements, such as those relating to the geographical distribution of BSE, have become obsolete. The chapters by Prusiner on prion diseases and kmberlin on BSE provide useful brief
